Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Patent
1997-08-12
1999-12-28
Degen, Nancy
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
435325, 514 44, 536 245, C12Q 168, C12N 1585, A61K 4800, C07H 2104
Patent
active
060079916
ABSTRACT:
A method is disclosed for inhibiting malignant neoplastic growth of epithelial or endothelial cells in a mammal by administering to the mammal an effective amount of an oligonucleotide complementary to at least a portion of mRNA for ERK-1 or ERK-2 that is overexpressed in the mammal. The antisense oligonucleotides are administered to the mammal as a dosage unit. A method of identifying and monitoring potentially malignant neoplastic cell growth in a mammal is also disclosed.
REFERENCES:
patent: 5525625 (1996-06-01), Bridges et al.
patent: 5582986 (1996-12-01), Monia et al.
patent: 5585479 (1996-12-01), Hoke et al.
patent: 5593884 (1997-01-01), Karin et al.
patent: 5597719 (1997-01-01), Freed et al.
Crooke et al., Basic Principles of Antisense Therapeutics, Antisense Research and Application, pp. 1-50, Jul. 7, 1998.
Rojanasakul et al., Antisense oligonucleotide therapeutics: drug delivery and targeting, Advanced Drug Delivery Reviews, vol. 18, pp. 115-131, 1996.
Gewirtz et al., Facilitating oligonucleotide delivery: helping antisense deliver on its promise, Proc. Natl. Acad. Sci., vol. 93, pp. 3161-3163, Apr. 1996.
Branch, A good antisense molecule is hard to find, TIBS, vol. 23, pp. 45-50, Feb. 1998.
Galvin-Parton et al., "In Vivo Analysis of Signaling Elements via Targeted, Inducible Antisense RNA", Methods in Molecular Genetics 8 362-372 (1996).
Gao et al., "Morphogen-Induced Decline in G.sub.1.alpha.2 Triggers F9 Teratocarcinoma Stem Cell Progression Via Phospholipase C and Mitogen-Activated Protein Kinase", The Journal of Biological Chemistry 271 9002-9008 (1996).
Brunet et al., "Le Module MAP Kinase: Role Dans Le Controle De La Proliferation Cellulaire", C. R. Soc. Biol. 189 43-57 (1995) (English Abstract).
Sale et al., "Requirement of MAP Kinase for differentiation of Fibroblasts to Adipocytes, for Insulin Activation of p90 S6 Kinase and for Insulin or Serum Stimulation of DNA Synthesis", The EMBO Journal 14 674-684 (1995).
Hunter, "Protein Kinases and Phosphatases: The Yin and Yang of Protein Phosphorylation and Signaling", Cell 80 225-236 (1995).
Cobb et al., "How MAP Kinases Are Regulated" The Journal of Biological Chemistry 270 14843-14846 (1995).
Nuovo et al., "Correlation of the in Situ Detection of Polymerase Chain Reaction-Amplified Metalloprotinase Complementary DNAs and Their Inhibitors with Prognosis in Cervical Carcinoma", Cancer Research 55 267-273 (1995).
Cobb, "The Role of the MAP Kinase Pathway in Breast Cancer", National Technical Information Service, Accession No. AB-8301 655/7/XAB (1995).
Stull et al., "Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects", Pharmaceutical Research 12 465-483 (1995).
Mansour et al., "Transformation of mammalian Cells by Constitutively Active MAP Kinase Kinase", Science 265 966-970 (1994).
Graff, "Messenger RNA Translation and Malignancy: The MRNA CAP-Binding Protein, EIF-4E, as an Integral Component of Malignancy in Cloned Rat", Dissertation, Chapter 6, 110-130 (1994).
Frost et al., "A Requirement for Extracellular Signal-Regulated Kinase (ERK) Function in the Activation of AP-1 by Ha-Ras, Phorbol 12-Myristate 12-Acetate, and Serum", Proc. Natl. Acad. Sci. USA 91 3844-3848 (1994).
Frost et al., "Simian Virus 40 Small t Antigen Cooperates with Mitogen-Activated Kinases to Stimulate AP-1 Activity", Molecular and Cellular Biology 14 6244-6252 (1994).
Voyno- Yasenetskaya et al., "Mutant .alpha. subunits of G12 and G13 Proteins Induce Neoplastic Transformation of Rat-1 Fibroblasts", Oncogene 9 2559-2565 (1994).
Brunet et al., "Constitutively Active Mutants of MAP Kinase Kinase (MEK1) Induce Growth-Factor-Relaxation and Oncogenicity When Expressed in Fibroblasts", Oncogene 9 3379-3387 (1994).
Janes et al., "Activation of the Ras Signaling Pathway in Human Breast Cancer Cells Overexpressing erbB-2", Oncogene 9 3601-3608 (1994).
Mansour et al., "Transformation of Mammalian Cells by Constitutively Active MAP Kinase Kinase", Science 265 966-970 (1994).
Robbins et al., "Map Kinases ERK1 and ERK2: Pleiotropic Enzymes in a Ubiquitous Signaling Network", Advances in Cancer Research 63 93-117 (1994).
Moxham et al., "Induction of G.alpha..sub.i2 -Specific Antisense RNA In Vivo Inhibits Neonatal Growth", Science Series 260 991-995 (1993).
Lippman, "The Development of Biological Therapies for Breast Cancer", Science 259 631-632 (1993).
Sontag, "The Interaction of SV40 Small Tumor Antigen with Protein Phosphatase 2A Stimulates the Map Kinase Pathway and Induces Cell Proliferation", Cell 75 887-897 (1993).
Blenis, "Signal Transduction Via the MAP Kinases: Proceed at Your Own RSK" Proc. Natl. Acad. Sci. USA 90 5889-5892 (1993).
Nuovo et al., "In Situ Detection of PCR-Amplified HIV-1 Nucleic Acids and Tumor necrosis Factor cDNA in Cervical Tissues", American Journal of Pathology 143 40-48 (1993).
Gupta et al., "MAP Kinase is Constitutively Activated in gip2 and src Transformed Rat HeLa Cells", The Journal of Biological Chemistry 267 7987-7990 (1992).
Allred et al., "Overexpression of HER-2
ew and Its Relationship with Other Prognostic Factors Change During the Progression of In Situ to Invasive Breast Cancer", Human Pathology 23 974-979 (1992).
Wang et al., "Antisense Oligodeoxynucleotides to G.sub.s Protein .alpha.-subunit Sequence Accelerate Differentiation of Fibroblasts to Adipocytes" Nature 358 334-337 (1992).
Kobayashi et al., "Estrogen Receptor, c-erbB-2 and nm23/NDP Kinase Expression in the Intraductal and Invasive Components of Human Breast Cancers" Jpn. J. Cancer Res. 83 859-865 (1992).
Allred et al., "HER-2
eu in Node-Negative Breast Cancer: Prognostic Significance of Overexpression Influenced by the Presence of In situ Carcinoma", Journal of Clinical Oncology 10 599-605 (1992).
Trojan et al., "Loss of Tumorigenicity of Rat Glioblastoma Directed by Episome-Based Antisense cDNA Transcription of Insulin-Like Growth Factor I", Proc. Natl. Acad. Sci. USA 89 4874-4878 (1992).
Seger et al., "Purification and Characterization of Mitogen-Activated Protein Kinase Activator(s) from Epidermal Growth Factor-Stimulated A431 Cells", The Journal of Biological Chemistry 267 14373-14381 (1992).
Boulton et al, "Identification of Multiple Extracellular Signal-Regulated Kinases (ERKs) with Antipeptide Antibodies", Cell Regulation 2 357-371 (1991).
Arteaga et al., "Elevated Content of the Tyrosine Kinase Substrate Phospholipase C-.gamma.1 in Primary Human Breast Carcinomas", Proc. Natl. Acad. Sci. USA 88 10435-10439 (1991).
Maguire et al., "Neu(c-erbB-2), a Tumor Marker in Carcinoma of the Female Breast", Pathobiology 58 297-303 (1990).
Maguire, Jr. et al., "Neu (c-erbB-2), a Tumor Marker in Carcinoma of the Female Breast", Pathobiology 58 297-303 (1990).
Slamon et al., "Studies of the HER-2
eu Proto-oncogene in Human Breast and Ovarian Cancer" Science 244 707-712 (1989).
Anfossi et al., "An Oligomer Complementary to c-myb-encoded mRNA Inhibits Proliferation of Human Myeloid Leukemia Cell Lines", Proc. Natl. Acad. Sci. USA 86 3379-3383 (1989).
Hudziak, "Amplified Expression of the HER2/ERBB2 Oncogene Induces Resistance to Tumor Necrosis Factor .alpha. in NIH 3T3 Cells", Proc. Natl. Acad. Sci. USA 85 5102-5106 (1988).
Muller et al., "Single-Step Induction of Mammary Adenocarcinoma in Transgenic Mice Bearing the Activated c-neu Oncogene", Cell 54 105-115 (1988).
"Amplification of c-erbB-2 and Aggressive Human Breast Tumors?", Science 240 1795-1798 (1988).
Wickstrom, "Human Promyelocytic Leukemia HL-60 Cell Proliferation and c-myc Protein Expression are Inhibited by an Antisense Pentadecadeoxynucleotide Targeted Against c-myc mRNA", Proc. Natl. Acad. Sci. USA 85 1028-1032 (1988).
Holt et al., "An Oligomer Complementary to c-myc mRNA Inhibits Proliferation of HL-60 Promyelocytic Cells and Induces Differentiation", Molecular and Cellular Biology 8 963-973 (1988).
Slamon, "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2
eu Oncogene", Science 235 177-235 (1987).
Di Fiore et al., "erbB-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells" Science 237 178-182 (1987).
Hudziak et al., "Incr
Malbon Craig C.
Sivaraman Vimala S.
Wang Hsien-yu
Degen Nancy
The Research Foundation of SUNY
Wang Andrew
LandOfFree
Antisense oligonucleotides for mitogen-activated protein kinases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense oligonucleotides for mitogen-activated protein kinases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotides for mitogen-activated protein kinases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2381345